Article

Metformin does not alter the risk of lung cancer: A case-control analysis

Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Switzerland
Lung cancer (Amsterdam, Netherlands) (Impact Factor: 3.74). 09/2012; 78(2):133-7. DOI: 10.1016/j.lungcan.2012.08.010
Source: PubMed

ABSTRACT Metformin use has been linked to a decreased cancer risk. We explored the association between use of metformin or other antidiabetic drugs and the risk of lung cancer.
We assessed the association between metformin, and other antidiabetic drugs and lung cancer using a case-control analysis in the UK-based General Practice Research Database (GPRD). Cases were people with an incident diagnosis of lung cancer. Up to 6 controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the GPRD. The contribution of potential confounders including tuberculosis, chronic obstructive pulmonary disease (COPD), diabetes mellitus, and co-morbid conditions to diabetes was evaluated in univariate models, and final results were adjusted for BMI and smoking.
Long-term use (≥40 prescriptions) of metformin was not associated with an altered risk of lung cancer (adj. OR 1.21, 95% CI 0.97-1.50. Long-term use of sulfonylureas was linked to a marginally decreased risk of lung cancer (adj. OR 0.74, 95% CI 0.60-0.90. This risk decrease was observed in men (adj. OR 0.64, 95% CI 0.50-0.83) but not in women (adj. OR 0.97, 95% CI 0.69-1.37) and this risk decrease was not statistically significant in an analysis restricted to diabetic patients only (adj. OR. 0.82, 95% CI 0.65-1.02). Long-term use of insulin was associated with a slightly increased risk of lung cancer (adj. OR 1.33, 95% CI 1.04-1.71); however, no consistent trend across duration strata was observed.
Metformin did not decrease the risk of lung cancer.

1 Follower
 · 
75 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess the correlation between metformin and risk of developing lung cancer by meta-analysis. Papers on the correlation between metformin and risk of lung cancer were searched from PubMed, MEDLINE, EMBASE, ISI Web of Science, and Cochrane Library. Six papers on case-control study were included in this study, involving 39,787 metformin users and 177,752 controls. Meta-analysis showed that the risk of developing lung cancer was lower in metformin users than in those without metformin (OR=0.55, 95% CI: 0.35-0.85, P<0.001). The risk of developing lung cancer is lower in metformin users than in those without metformin.
    08/2013; 2(4):259-63. DOI:10.3978/j.issn.2218-6751.2013.08.01
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rational: Prior studies have shown an anticancer effect of metformin in patients with breast and colorectal cancer. It is unclear, however, whether metformin has a mortality benefit in lung cancer. Objectives: To compare overall survival of diabetic patients with stage IV non-small cell lung cancer (NSCLC) taking metformin versus those not on metformin. Methods: Using data from the Surveillance, Epidemiology and End Results registry linked to Medicare claims, we identified 750 diabetic patients 65-80 years of age diagnosed with stage IV NSCLC between 2007 and 2009. We used propensity score methods to assess the association of metformin use with overall survival while controlling for potential confounders. Measurements and Main Results: Overall, 61% of patients were on metformin at time of lung cancer diagnosis. Median survival in the metformin group was five months, compared to three months in patients not treated with metformin (p<0.001). Propensity score analyses showed that metformin use was associated with a statistically significant improvement in survival (hazard ratio: 0.80, 95% confidence interval 0.71 to 0.89), after controlling for sociodemographics, diabetes severity, other diabetes medications, cancer characteristics, and treatment. Conclusions: Metformin is associated with improved survival among diabetic patients with stage IV NSCLC suggesting a potential anticancer effect. Further research should evaluate plausible biological mechanisms as well as test the effect of metformin in prospective clinical trials.
    American Journal of Respiratory and Critical Care Medicine 12/2014; 191(4). DOI:10.1164/rccm.201407-1395OC · 11.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Methodologic biases may explain why observational studies examining metformin use in relation to lung cancer risk have produced inconsistent results. We conducted a cohort study to further investigate this relationship, accounting for potential biases. For 47,351 patients with diabetes ages ≥40 years, who completed a health-related survey administered between 1994 and 1996, data on prescribed diabetes medications were obtained from electronic pharmacy records. Follow-up for incident lung cancer occurred from January 1, 1997, until June 30, 2012. Using Cox regression, we estimated lung cancer risk associated with new use of metformin, along with total duration, recency, and cumulative dose (all modeled as time-dependent covariates), adjusting for potential confounding factors. During 428,557 person-years of follow-up, 747 patients were diagnosed with lung cancer. No association was found with duration, dose, or recency of metformin use and overall lung cancer risk. Among never smokers, however, ever use was inversely associated with lung cancer risk [HR, 0.57; 95% confidence interval (CI), 0.33-0.99], and risk appeared to decrease monotonically with longer use (≥5 years: HR, 0.48; 95% CI, 0.21-1.09). Among current smokers, corresponding risk estimates were >1.0, although not statistically significant. Consistent with this variation in effect by smoking history, longer use was suggestively associated with lower adenocarcinoma risk (HR, 0.69; 95% CI, 0.40-1.17), but higher small cell carcinoma risk (HR, 1.82; 95% CI, 0.85-3.91). In this population, we found no evidence that metformin use affects overall lung cancer risk. The observed variation in association by smoking history and histology requires further confirmation. Cancer Prev Res; 8(2); 174-9. ©2014 AACR. ©2014 American Association for Cancer Research.
    Cancer Prevention Research 02/2015; 8(2):174-9. DOI:10.1158/1940-6207.CAPR-14-0291 · 5.27 Impact Factor